Search International and National Patent Collections

1. (WO2018044105) IL-21 (HETERODIMERIC FC-FUSED IL-21) FUSED TO IMMUNOGLOBULIN HEAVY CHAIN CONSTANT REGION HETERODIMER (HETERODIMERIC FC), AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

Pub. No.:    WO/2018/044105    International Application No.:    PCT/KR2017/009570
Publication Date: Fri Mar 09 00:59:59 CET 2018 International Filing Date: Fri Sep 01 01:59:59 CEST 2017
IPC: C07K 14/54
A61K 38/20
A61K 45/06
A61K 47/68
Applicants: KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION
고려대학교 산학협력단
AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
아주대학교산학협력단
Inventors: LEE, Kyung-Mi
이경미
LIM, Seon Ah
임선아
KIM, Yong Sung
김용성
KIM, Ye Jin
김예진
Title: IL-21 (HETERODIMERIC FC-FUSED IL-21) FUSED TO IMMUNOGLOBULIN HEAVY CHAIN CONSTANT REGION HETERODIMER (HETERODIMERIC FC), AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
Abstract:
The present invention relates to: a heterodimer fusion protein (heterodimeric Fc-fused protein) containing first and second Fc regions of an immunoglobulin heavy chain constant region pair and in which IL-21 is bound to the N-terminus and/or C-terminus of the first and/or second Fc region(s), and characterized in that CH3 domains of the first and second Fc regions are modified such that the formation of a heterodimer can be promoted; and a pharmaceutical composition containing the heterodimeric Fc-fused protein. When the immunoglobulin heavy chain constant region heterodimeric Fc-fused protein according to the present invention is used, the in vivo half-life of IL-21 included in the heterodimeric Fc-fused protein can be remarkably increased.